Compare ASR & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASR | ARWR |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.0B |
| IPO Year | 2001 | 2009 |
| Metric | ASR | ARWR |
|---|---|---|
| Price | $270.19 | $49.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $324.22 | $107.71 |
| AVG Volume (30 Days) | 47.9K | ★ 1.9M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $3.14 | N/A |
| Revenue Next Year | $22.46 | N/A |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $226.19 | $37.06 |
| 52 Week High | $381.52 | $95.49 |
| Indicator | ASR | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 70.54 | 23.65 |
| Support Level | $257.47 | N/A |
| Resistance Level | $314.70 | $66.37 |
| Average True Range (ATR) | 6.25 | 2.66 |
| MACD | 2.05 | -0.65 |
| Stochastic Oscillator | 91.98 | 16.30 |
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The company's operating segments are Cancun, which generates majority revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.